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Background. Bevacizumab (BEV), a humanized immunoglobulin G1 monoclonal antibody that inhibits VEGF has demonstrated
activity against recurrent high-grade gliomas (HGG) in phase II clinical trials. Patients and Methods.D a t aw e r ec o l l e c t e df r o m
patients with recurrent HGG who initiated treatment with BEV outside a clinical trial protocol at two Belgian university hospitals.
Results. 19 patients (11 M/8 F) were administered a total of 138 cycles of BEV (median 4, range 1–31). Tumor response assessment
by MRI was available for 15 patients; 2 complete responses and 3 partial responses for an objective response rate of 26% for the
intent to treat population were observed on gadolinium-enhanced T1-weighted images; signiﬁcant regressions on T2/FLAIR were
documented in 10 out of 15 patients (67%). A reduced uptake on PET was documented in 3 out of 4 evaluable patients. The
six-month progression-free survival was 21% (95% CI 2.7–39.5). Two patients had an ongoing tumor response and remained free
from progression after 12 months of BEV treatment. Conclusions. The activity and tolerability of BEV were comparable to results
from previous prospective phase II trials. Reduced uptake on PET suggests a metabolic response in addition to an antiangiogenic
eﬀect in some cases with favorable clinical outcome.
1.Introduction
Gliomas are the most frequent primary tumors of the central
nervous system (CNS) and represent approximately 2% of
all malignant diseases. Their annual incidence is about 11.5
new cases per 100.000 persons per year [1, 2]. The WHO
classiﬁcation of tumors of the central nervous system distin-
guishes the subtypes of glioma according to morphology and
grade [3]. High-grade gliomas (HGG, WHO-grade 3 and 4
glioma) are malignant tumors with a poor survival outcome.
In a pivotal phase III trial, where patients diagnosed with
glioblastoma (GB, WHO-grade IV glioma) who were treated
with postoperative radiation therapy (RT) and concomitant
temozolomide (TMZ) followed by six cycles of adjuvant
TMZ,themediansurvivalwas14,6months,whiletheoverall
survival (OS) was 27.2% at 2 years, 16.0% at 3 years,
12.1% at 4 years, and 9.8% at 5 years [4]. The prognosis of
patients with WHO-grade III glioma is superior to that of
GB patients but much more heterogeneous and correlated
with the histopathological and molecular-genetic subtype
[5, 6]. Following initial resection and postoperative RT,
anaplastic gliomas recur after a median of 2-3 years. Most2 Journal of Oncology
often, recurrent grade III glioma will have transformed into
a more aggressive tumor at recurrence (a so-called sec-
ondary glioblastoma). The survival of patients with recurrent
high-grade glioma following prior therapy with alkylating
chemotherapy is grim and no treatment has demonstrated
to improve the survival in a randomized clinical trial [6, 7].
HGG are among the most angiogenic tumors and typ-
ically express high amounts of vascular endothelial growth
factor (VEGF). VEGF is a key molecular mediator of tumor-
associated neoangiogenesis and its expression level has been
correlated with tumor vascularisation, WHO-grade and
prognosis [8, 9]. HGG also express the VEGF-receptors and
frequently carry an amplicon of chromosome 4q12 com-
prising the VEGF-receptor-2 (VEGFR2), PDGFR-alfa, and
cKITgenesin23–30%ofcases[10–12].Coexpressionand/or
ampliﬁcation of both the VEGF and VEGFR2 constitute an
autocrine/paracrine loop.
Bevacizumab (BEV; Avastin, Roche, Basel, Switzerland)
is a humanized immunoglobulin G1 monoclonal antibody
that binds to and inhibits VEGF. It has proven to be active
in combination with cytotoxic agents and is registered by the
FDA and EMA as part of a combination treatment regimen
with chemotherapy for metastatic colorectal cancer, non-
small-celllungcancer,andbreastcancer,andincombination
withinterferon-alfainmetastaticrenalcellcarcinoma[8,13–
19].
On May 5, 2009, the FDA granted acceleratedapproval to
bevacizumab as a single agent for the treatment of patients
with recurrent glioblastoma. The approval was based on
the results of two phase II clinical trials (AVF3708g and
NCI 06-C-0064E) [20]. The largest phase II trial, involving
a total of 167 patients with recurrent GB, randomized
patients between treatment with BEV (at a biweekly dose
of 10mg/kg) in one arm and the combination of BEV (at
the same dose) and irinotecan in a second arm [20]. In the
bevacizumab-alone and the bevacizumab-plus-irinotecan
groups, the objective response rates were 28.2% and 37.8%,
and the estimated 6-month progression-free survival rates
were 42.6% and 50.3%, respectively. The number of adverse
events in the BEV plus irinotecan population was higher
(65.8%versus46.4%grade ≥3adverseevents),whilemedian
o v e r a l ls u r v i v a lt i m e sw a sc o m p a r a b l eb e t w e e nt h et w oa r m s
(9.2 months and 8.7 months, resp., compared to 7.5 months
in a historical population [7]).
In a single-arm phase II trial, investigating the sequential
use of BEV and the combination of BEV and irinotecan, no
activity was found for the combination after failure of BEV
as a single agent [21]. BEV has also demonstrated antitumor
activity as a single agent in patients with recurrent anaplastic
glioma [22, 23]; in combination with a variety of cytotoxic
agents [24–26], and when administered on a once every 3-
week schedule (at a dose of 15mg/kg every 3 weeks) [27].
MRI-based tumor evaluation in patients treated for
recurrent glioma have been characterized by a rapid regres-
sion of tumor-associated edema and restoration of the
blood-brain/tumor barrier. Progression of disease by dif-
fuse, non-gadolinium-enhancing inﬁltration of the brain
(=gliomatosis) may occur in patients that respond to BEV
[28]. Notwithstanding these atypical patterns of progression,
updated overall survival of the patients treated in the
BRAIN (AVF3708g) study indicated that 16% of patients
remained alive at 30 months of followup, a percentage that
compares favorably with historical controls [29]. Besides the
eﬀect of BEV on glioma-associated vasculature, responses
documented by positron emission tomography (PET) using
ﬂuorothymidine (FLT), an imaging marker of cell prolifer-
ation, were correlated with an improved overall survival in
patients treated with irinotecan and BEV [30, 31].
On 19 November 2009, the CHMP (EMA) refused to
change the terms of the marketing authorization for beva-
cizumab in the EU to include recurrent glioblastoma. From
ApriltoNovember2009,theBelgianRIZIV/INAMIprovided
partial (60%) reimbursement for bevacizumab following an
individual request to the “bijzonder Solidariteitsfonds/Fonds
Sp´ ecial de Solidarit´ e.” This paper reports the ﬁrst experience
with bevacizumab for recurrent glioma in patients treated at
two Brussels university hospitals.
2. Patients andMethods
2.1. Data Collection. This observational (noninterventional)
study was performed with the clinical data that were retro-
spectively retrieved from the medical ﬁles of all patients with
recurrent high-grade glioma who initiated BEV treatment
between 9 January 2009 and 27 January 2010. These patients
represent the ﬁrst patients treated with BEV for recurrent
glioma at two Belgian University hospitals, the UZ Brussel
and ULB Erasme.
We collected data regarding the general clinical and
neurological evolution during BEV treatment, the BEV
treatment disposition (Table 3), as well as laboratory tests
performed during BEV therapy. Adverse events were clas-
siﬁed according to the Common Terminology Criteria for
Adverse Events v3.0 (CTCAE). Tumor response assessment
on MRI was based on the Macdonald criteria [32]. In
accordance, we made the sums of the maximal cross-
sectional radii of the contrast enhancing tumor measured
by consecutive contrast MR. A complete response (CR) was
deﬁned as a disappearance of all contrast enhancing tumor,
with the patient neurologically improved or stable and oﬀ
corticosteroids. A partial response (PR) was deﬁned as a
50% or more decrease in the size of the contrast-enhancing
tumorwiththepatientneurologicallyimprovedorstableand
with the corticosteroid dose stable or decreased. Progressive
disease (PD) was deﬁned as a 25% or more increase in
the size of the contrast enhancing tumor or appearance of
a separate tumor. Stable disease (SD) was deﬁned for all
other situations. In addition, we assessed the abnormalities
on sequential T2 and FLAIR MRI—sequences in a similar
fashion, and changes on PET—scan of the brain for the
subgroup of patients evaluated by this imaging modality.
2.2. Statistical Analysis. BEV treatment disposition, BEV-
related adverse events, demographic and baseline patient,
and disease characteristics were summarized using descrip-
tive statistics. Kaplan-Meier statistics were used to estimate
theprobabilityofsurvival(SPSSInc.,Chicago,Illinois60606,
USA).Journal of Oncology 3
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Figure 1: Maximal % change in tumor surface area on gadolinium-
enhanced T1-weighted MRI (Blue bar) and surface area of nonen-
hancing lesions on T2-weighted MRI (Red bar) as compared to
baseline during BEV therapy. Patient no. 14 had a decrease of
the measured contrast-enhancing lesion; however, a new contrast-
enhancing lesion appeared in a diﬀerent location.
3. Results
3.1. Baseline Patient Characteristics. Nineteen patients (11
men and 8 women) with recurrent supratentorial HGG
w e r ei d e n t i ﬁ e dt oh a v er e c e i v e dt r e a t m e n tw i t hB E Vf o r
progressive disease following failure after prior treatment
including surgery, radiation therapy, and chemotherapy.
Baseline patient characteristics are summarized in Table 1.
The median patient age at the initiation of BEV treatment
was 40 years (range 28 to 70). Eighty-nine percent of the
patients were younger than 50 years at the start of BEV
treatment. Eight (53%) patients had a pathological diagnosis
of primary GB, 4 (21%) of secondary GB, and 5 (26%) of
recurrent grade III glioma. The median baseline Karnofsky
performance score (KPS) was 70. Five (26%) patients had
a baseline KPS of 60% or lower. In six patients, initial
treatment consisted of surgery followed by radiotherapy.
In 13 patients, the initial treatment consisted of surgery,
followed by RT with concomitant TMZ and adjuvant TMZ
(median number of adjuvant TMZ cycles: 6, range 1 to
12). Six of these patients experienced progression during
adjuvant TMZ treatment. Three patients had been treated
with radiation therapy at recurrence (one patient was
administered fractionated radiotherapy at a dose of 55,5Gy,
twopatientsweretreatedusingγ-kniferadiosurgery).Twelve
patients underwent additional modalities of salvage therapy
for recurrent disease (chemotherapy, dendritic cell vaccina-
tion) before initiating BEV therapy.
3.2. Bevacizumab Treatment Disposition. Three patients ini-
tiatedBEVatadoseof5mg/kgevery2weeks(inoneofthem,
the dose was escalated to 10mg/kg every 2 weeks after the
ﬁrst administration), 14 patients at a dose of 10mg/kg every
2 weeks, and 2 patients at a dose of 15mg/kg every 3 weeks,
according to BEV administration regimens published in the
literature [20, 21, 24, 27, 33–35].
A total number of 123 BEV treatment cycles were ana-
lyzed in this study. Treatment was ongoing in 2 patients
at the time of this analysis. A median number of 4 cycles
were administered per individual patient (range 1 to 16).
Table 1: Patient baseline characteristics.
Variable No. of patients %
Treated population 19 100
Age of treated population
Median (range) 40 (28 to 70)
Sex of treated population
Male/female 11/8 58/42
Tumor location
Frontal 9 47
Temporal 5 26
Parietal 3 16
Occipital 1 5
Thalamus 1 5
Initial tumor histology
Astrocytoma 1 5
Anaplastic astrocytoma 3 16
Anaplastic oligodendroglioma 1 5
Anaplastic oligoastrocytoma 5 26
Glioblastoma 9 47
Latest tumor histology
Anaplastic astrocytoma 2 10
Anaplastic oligodendroglioma 0 0
Anaplastic oligoastrocytoma 3 16
Glioblastoma 14 74
Surgery at primary diagnosis 18 95
Total resection 6∗ 32
Subtotal resection 7 37
Biopsy 3∗ 16
Unknown extent 3 16
Radiotherapy at primary diagnosis 19 100
Concurrent temozolomide 15 79
Adjuvant temozolomide 13 68
Surgery for relapse 10 53
Radiotherapy for relapse 3 16
Fractionated 1 5
γ-knife 2 11
Temozolomide for relapse 7 37
Salvage therapy prior to BEV therapy◦ 12 63
CCNU 3 16
Dendritic cell vaccine 4 21
PCV 2 11
REGAL study: CCNU+cediranib/placebo 5 26
Sutent study: Sunitinib/CCNU 3 16
∗One patient had a biopsy, followed by gross tumor resection.
◦Seven patients had one salvage therapy prior to BEV therapy.
Five patients had the salvage therapies prior to BEV therapy.
There were no dose reductions of BEV. Three patients were
simultaneously treated with a cytotoxic drug (hydroxyurea,4 Journal of Oncology
Table 2: BEV related adverse events.
Description Grade 1 Grade 2 Grade 3 Total Treatment regimen
Likely related to BEV therapy
H y p e r t e n s i o n 110 21 0 m g / k g / 2 w e e k s
Epistaxis 0 1 0 1 10mg/kg/2weeks
U l c e r a t i o n s k i n 101 21 0 m g / k g / 2 w e e k s
H e m a t o c h e z i a 100 1 1 cycle at 5mg/kg/2weeks;
9c y c l e sa t1 0m g / k g / 2 w e e k s
Subungual hemorrhage 1 0 0 1 10mg/kg/2weeks
Wound dehiscence 0 1∗ 0 1 10mg/kg/2weeks
Abdominal pain syndrome 0 0 1 1 10mg/kg/2weeks
T o t a l 432 9
∗Occurred more than 2 months after termination of BEV therapy.
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Figure 2: Change in tumor surface area in time during BEV
treatment in 15 patients evaluable on gadolinium-enhanced T1-
weighted MRI. Patient no. 14 had a decrease of the measured con-
trast-enhancing lesion; however, a new contrast-enhancing lesion
appeared in a diﬀerent location.
TMZ, or CCNU). Fourteen patients (74%) were treated with
corticosteroids at the initiation of BEV treatment. The dose
of corticosteroids could be tapered in 4 patients and stopped
in two of them.
3.3. Treatment-related Adverse Events. Nine BEV-related
adverse events were encountered, of which none were grade
4o r5( Table 2). Two grade 3 adverse events (ulceration of
skin striae and an abdominal pain syndrome) necessitated
stopping BEV administration in the absence of documented
tumor progression.
3.4. Antitumor Activity and Survival. Four patients (21%)
experienced a rapid increase in disease-related symptoms
aftertheinitiationofBEV.Theirclinicalconditionprohibited
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Figure 3: Change in the surface area of nonenhancing lesions in
timeduringBEVtreatmentin14patientsevaluableonT2-weighted
MRI.
an objective tumor evaluation with MRI after the initiation
ofBEV.Inall4patients,clinicaldeteriorationwasconsidered
related to progression of disease.
Fifteen (79%) patients were assessable for tumor res-
ponseonT1gadolinium-enhancedMRI-sequences(Gd-T1).
Tumor regression was complete in 2 patients and more
than 50% in an additional 3 patients. This correlates to an
objective response rate of 33% according to the MacDonald
criteria for the 15 evaluable pts on MRI and 26% for
the intent to treat population. All of these patients had
stabilization or improvement of disease-related symptoms
and none of them had an increase in corticosteroid dose.
Seven patients (47%) obtained a stable disease, and 3
(20%)patientsexperiencedimmediateprogressionofdisease
during BEV therapy (Figures 1 and 2).
Assessment of tumor response by T2/FLAIR MRI-
sequences was available for the same 15 patients who wereJournal of Oncology 5
T1 + Gd 14/8/2009
(a)
T1 + Gd 11/9/2009
(b)
T2 14/8/2009
(c)
T2 11/9/2009
(d)
11C-Methionine PET 10/7/2009
(e)
11C-Methionine PET 7/10/2009
(f)
Figure4:CaseillustrationofatumorresponseonBEVtherapy.Baselineimagesbygadolinium-enhancedT1MRI,T2,and11C-Methionine-
PET on the left hand (top to bottom) and images obtained after 2 administrations of BEV. The patient remained free from progression after
more than 1 year of BEV therapy.
Table 3: BEV treatment disposition.
Variable Total (median, range)
Number of BEV cycles 123 (4, 1–16)
Number of patients (%)
Patients treated at a dose of 5mg/kg
every 2 weeks 3∗ (15,8)
Patients treated at a dose of 10mg/kg
every 2 weeks 15∗ (78,9)
Patients treated at a dose of 15mg/kg
every 3 weeks 2 (10,5)
∗One patient had a dose escalation from 5 to 10mg/kg every 2 weeks after
the ﬁrst cycle.
evaluable by T1-weighted MRI. Complete disappearance of
nonenhancing lesions was observed in 1 patient, and partial
regression was observed in 6 additional patients (47%; for
an objective tumor response according to the RANO criteria
of 37%). No change was observed in four patients (27%),
and an increase of abnormalities at the ﬁrst evaluation was
observed in 4 patients (27%) (Figures 1 and 3).
Four patients were evaluated by 2-(18F)-Fluoromethyl-
L-phenylalanine PET (FMP-PET) or 11C-Methionine-PET
of the brain before and during BEV treatment. A reduced
uptake of amino-acid tracer on PET-scan was documented
in 3 out of 4pts during BEV treatment, in 2 patients with
the most favorable progression-free survival, and a complete
normalization of PET-tracer uptake was observed during
BEV therapy (Figure 4).
As of October 2010 (the time of this analysis), 16
patients had died, all disease related. One patient was lost
to follow-up after progression on BEV therapy. Two patients
(10,5%) remained free-from progression after 1 year of BEV
treatment. In one of these patients BEV was stopped after
1-year of therapy in the absence of metabolic activity on
methionine-PET and normalization of gadolinium enhance-
ment on T1-MRI. Three months after stopping BEV, the
patient developed progression of disease. The second patient
developed progression of disease following 18 months of
remission on BEV therapy.
The six-month progression-free survival rate (6mPFS%)
was 21% (95% CI 2.7–39.5), and the 6mOS% was 47.4%
(95% CI 24.8–69.9). The median PFS and overall survival6 Journal of Oncology
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Figure 5: Kaplan-Meier progression-free survival and overall
survivalestimates.OS—overallsurvival,TTP—timetoprogression.
The 6mPFS% was 21% (95% CI 2.7–39.5); the 6mOS% was 47.4%
(95% CI 24.8–69.9). The median PFS was 10 weeks (95% CI 2–25);
the median OS was 25 weeks (95% CI 17–32).
(OS) were 10 weeks (95% CI 2–25) and 25 weeks (95% CI
17–32), respectively (Figure 5).
4. Discussion
High-grade gliomas are highly aggressive and therapy resis-
tant malignant tumors. With contemporary standard treat-
ment options for patients diagnosed with GB, the prognosis
remains grim and most patients do not survive for more
than 2 years following the diagnosis [4]. Salvage therapies
with cytotoxic agents are seldom successful (<10% ORR)
[7, 36]. Uncontrolled clinical studies with the VEGF tar-
geted IgG1 monoclonal antibody bevacizumab have shown
unprecedented tumor response rates and survival outcomes
that compare favorably with historical control series. Within
thecontextoftheseprospectiveclinicaltrials,BEV-associated
toxicities have been acceptable and reﬂect a typical spectrum
of side eﬀects that are associated with VEGF(R) targeted
therapies. As most of the prospective trials have used quite
stringent patient recruitment criteria, safety and activity of
BEVwhenusedoutsideofaclinicaltrialmeritconsideration.
We, therefore, retrospectively analyzed the clinical out-
come of nineteen patients treated with BEV for recurrent
HGG during the ﬁrst year that BEV became available in
this indication at two university hospitals in Belgium. As
expected, the baseline characteristics of the patients included
in our analysis compared unfavorably with those of the
patients treated in the pivotal phase II trial [20]. A larger
proportion of patients treated in our series were treated
at second or third relapse, and the baseline KPS was less
or equal to 60% in a signiﬁcant proportion of patients.
Nevertheless, BEV therapy was generally well tolerated. We,
therefore, consider that the results from our study, although
preliminary, indicate that the safety proﬁle of BEV for recur-
rent HGG outside the context of a prospective clinical trial
is comparable to what has been reported in the literature.
Nevertheless, two patients needed to stop treatment because
of BEV-related side eﬀects in the absence of documented
progression. It, therefore, needs to be considered that frail
patients might be at higher risk for BEV-related adverse
events. The objective tumor response, either analyzed by
gadolinium-enhanced T1 MRI and/or T2/FLAIR imaging,
was interestingly high in our patient population. Reﬂecting
the poor baseline prognostic characteristics of our popula-
t i o n ,b o t ht i m et op r o g r e s s i o n( T T P )a n do v e r a l ls u r v i v a l
(OS), in contrast, were low when compared to published
series. However, two patients in our series experienced a
durable complete response and progression-free survival for
over 1 year following BEV therapy for recurrence, indicating
the potential for a durable therapeutic eﬀect in a subgroup of
patients.
Patterns of tumor response and progression during
antiangiogenic therapy are a matter of controversy in the
recent literature. In our small series, the tumor response
pattern to BEV was heterogeneous and could be divided
in three distinct patterns. A ﬁrst group of patients demon-
strated no evidence of response (clinical or radiological) to
bevacizumab therapy. Such was the case in four patients,
who deteriorated rapidly and could not be evaluated by
MRI, and three (20%) of the ﬁfteen assessable patients on
gadolinium-enhanced T1 MRI. A second group of patients
initially responded to therapy on gadolinium-enhanced T1
MRI, but subsequently showed early (<6 months) regrowth
of the gadolinium-enhancing tumor mass (n = 7; 47%)
or deteriorated clinically without characteristic increase in
the diameter of gadolinium-enhancing T1 MRI abnormities
(n = 3, 20%). In these 3 patients, there was a marked
progression of abnormalities on T2/FLAIR MRI, most likely
representing VEGFR-independent tumor cell inﬁltration of
the brain. A small third group of patients (2 patients; 13%)
experienced a very favorable and sustained tumor response
to BEV therapy, evident on both Gd-T1 and T2/FLAIR
MRI. Further useful diﬀerentiation of response to BEV may
be obtained by metabolic tumor imaging using PET. PET-
imaging has proven to be useful in assessing the response
of recurrent glioma treated with a variety of modalities.
Likewise, FLT-PET has been correlated with clinical outcome
of patients treated with the combination of irinotecan and
bevacizumab [30]. In our series, normalization in PET tracer
accumulation was observed in the 2 cases with the most
favorable evolution on MRI and survival. These case obser-
vations indicate that single agent BEV can be associated with
a reduction of PET-tracer uptake by the tumor, suggestive of
am e t a b o l i ce ﬀect. These observations merit further study
of PET as a tool for response assessment in patients with
recurrent glioma treated by BEV. PET response may be moreJournal of Oncology 7
predictive for survival as opposed to response assessment by
MRI.
We conclude that our analysis of the ﬁrst experience
with BEV for the treatment of patients with recurrent HGG
is in line with the reported tolerability and activity of this
new treatment from prospective clinical studies. Our obser-
vations support the usefulness of BEV as a new treatment
option for patients with recurrent HGG taken into account
the absence of alternative treatment options with proven
activity. Further observational study of the use of BEV in this
indication should be considered to optimize its use in daily
practice. Correlative studies between clinical, radiological,
PET parameters with molecular-genetic features of the HGG
should be conducted to provide predictive markers for
response and survival beneﬁt from BEV.
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